← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2001Last known activity
Jan 31, 2023
Acquired by Infinity Pharmaceuticals, Inc. on Jul 14, 2023
Timeline
2000s
- Jun 1, 2000
MEI Pharma— Founded
2020s
- Jul 14, 2023
Infinity Pharmaceuticals, Inc.— Acquired By
Drugs by trial phase (21 distinct, 16 trials)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Preleukemia
- Primary Myelofibrosis
- Prostatic Neoplasms
- Syndrome
Recent trials (20)
- NCT05604417CollaboratorPhase 1/Phase 2Jan 31, 2023
- NCT05209308Lead sponsorPhase 2Nov 30, 2022
- NCT04745832Lead sponsorPhase 3Apr 1, 2021
- NCT03768505Lead sponsorPhase 2Dec 15, 2018
- NCT03547115Lead sponsorPhase 1May 31, 2018
- NCT03151304Study directorPhase 2Jun 1, 2017
- NCT02914938Lead sponsorPhase 1Oct 1, 2016
- NCT02521389Lead sponsorPhase 1Jun 1, 2015
- NCT02267278CollaboratorPhase 2Jan 12, 2015
- NCT02100007Study directorPhase 1/Phase 2Apr 1, 2014
- NCT02100007Lead sponsorPhase 1/Phase 2Apr 1, 2014
- NCT01544322Study chairPhase 1May 1, 2012
- NCT01544322Lead sponsorPhase 1May 1, 2012
- NCT01401868Lead sponsorPhase 1Sep 1, 2011
- NCT01401868Study chairPhase 1Sep 1, 2011
Details
- Founded
- San Diego, CA, US Jun 1, 2000
- Last known activity
- Jan 31, 2023